Pathophysiology: Immune Dysfunction
1 Autoantibodies and G-Protein Coupled Receptors
Full Citation:: Wirth K, Scheibenbogen C. Autoantibodies to Vasoregulative G-Protein-Coupled Receptors Correlate with Symptom Severity, Autonomic Dysfunction and Disability in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Journal of Clinical Medicine. 2021;10(16):3675. DOI:: 10.3390/jcm10163675 PMID:: 34441971 PMCID:: PMC8397061 Key Findings:: Anti-\(\beta\) 2, M3, M4 receptor antibodies elevated; correlate with fatigue and muscle pain severity.
Full Citation:: M"uller JA, Subburayalu J, Winkler F, et al. Dysregulated autoantibodies targeting vaso- and immunoregulatory receptors in Post COVID Syndrome correlate with symptom severity. Frontiers in Immunology. 2022;13:981532. DOI:: 10.3389/fimmu.2022.981532
Full Citation:: Stein E, Heindrich C, Wittke K, et al. Efficacy of repeated immunoadsorption in patients with post-COVID myalgic encephalomyelitis/chronic fatigue syndrome and elevated \(\beta\) 2-adrenergic receptor autoantibodies: a prospective cohort study. The Lancet Regional Health – Europe. 2025;48:101161. DOI:: 10.1016/j.lanepe.2024.101161 PMID:: 39759581 Published:: February 2025 Study Design:: Prospective cohort study Key Findings:: Repeated immunoadsorption treatment in post-COVID ME/CFS patients with elevated \(\beta\) 2-adrenergic receptor autoantibodies showed symptom improvement in an uncontrolled prospective cohort (n=20). Provides hypothesis-strengthening evidence for autoantibody-targeted therapy in a biomarker-selected subgroup. Relevance:: Largest prospective cohort to date for immunoadsorption in post-COVID ME/CFS. Supports further investigation of autoantibody-targeted therapy in biomarker-selected patients. Cannot confirm efficacy without sham control: invasive multi-session procedures typically produce substantial placebo responses, and the absence of a control arm prevents distinguishing specific from non-specific effects. Certainty:: Medium (prospective design, published in Lancet Regional Health, targeted patient selection based on biomarker, n=20; however, no sham/control arm; open-label; cannot rule out placebo effects from invasive procedure). Mechanistic evidence for autoantibody pathogenicity: Medium. Efficacy evidence: Low-Medium pending sham-controlled replication.
Full Citation:: T"olle M, Freitag H, Antelmann M, et al. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Efficacy of Repeat Immunoadsorption. Journal of Clinical Medicine. 2020;9(8):2443. DOI:: 10.3390/jcm9082443 PMID:: 32751659 Published:: August 2020 Study Design:: Follow-up pilot study (n=5), retreating previously responsive ME/CFS patients Key Findings:: Repeat immunoadsorption (approximately 2 years after initial treatment) achieved 80–90% decline in total IgG and \(\beta\) 2AR-AB. 4/5 patients showed symptom improvement lasting 6–12 months. Modified protocol was well tolerated. Demonstrates feasibility of repeated IA cycles with sustained biomarker reduction. Relevance:: First study to examine repeat IA in ME/CFS; addresses the key clinical question of whether retreatment can re-establish and prolong response. Complements Scheibenbogen 2018 (initial treatment) and provides basis for multi-cycle strategies tested in Stein 2024. Certainty:: Low-Medium (n=5; open-label; no sham control; selected for prior response; small pilot only. Mechanistic plausibility: High).
Full Citation:: Stein E, Heindrich C, Wittke K, et al. Observational Study of Repeat Immunoadsorption (RIA) in Post-COVID ME/CFS Patients with Elevated \(\beta\) 2-Adrenergic Receptor Autoantibodies—An Interim Report. Journal of Clinical Medicine. 2023;12(19):6428. DOI:: 10.3390/jcm12196428 PMID:: 37835071 Published:: October 2023 Study Design:: Interim report of prospective observational study; n=10 at time of publication Key Findings:: 7/10 (70%) patients responded, defined by \(\geq\) 10-point increase in SF-36 Physical Function at week 4. Responders also improved in fatigue severity, muscle pain, headache, and cognitive symptoms. Published as interim analysis; the full cohort (n=20) was reported in Stein 2024 (Lancet Regional Health). Relevance:: Bridge publication between the Scheibenbogen 2018 pilot and the definitive Stein 2024 cohort study. Demonstrates consistent response rates across the Charit'e cohort and refines responder criteria. Certainty:: Low-Medium (interim analysis, n=10, open-label observational, no sham control; selection bias for elevated autoantibodies).
Full Citation:: Pre{}ler H, Machule M-L, Ufer F, et al. IA-PACS-CFS: a double-blinded, randomized, sham-controlled, exploratory trial of immunoadsorption in patients with chronic fatigue syndrome (CFS) including patients with post-acute COVID-19 CFS (PACS-CFS). Trials. 2024;25(1):172. DOI:: 10.1186/s13063-024-07982-5 PMID:: 38454468 ClinicalTrials:: NCT05710770 Published:: March 2024 (protocol paper) Study Design:: Published protocol for double-blind, randomized, sham-controlled trial; 2:1 allocation (active:sham); 66 patients; Charit'e Universit"atsmedizin Berlin Key Findings:: Protocol paper only — no efficacy results. 5 IA sessions administered every other day during 9–12 day inpatient hospitalization. Primary outcome: Chalder Fatigue Scale at 3 months. Quadruple-masked (participant, care provider, investigator, outcomes assessor). Trial completed October 2025; results pending publication. Relevance:: First sham-controlled RCT of immunoadsorption in ME/CFS. Critical for establishing whether IA benefits are specific (autoantibody removal) or non-specific (placebo, hospitalization, nursing attention). The 2:1 design maximizes power in the active arm while maintaining blinded control. Results will determine whether the Stein 2024 observational cohort findings replicate under controlled conditions. Certainty:: Protocol only — efficacy certainty pending. Trial design: High quality (double-blind, sham-controlled, pre-registered, quadruple-masked).
Full Citation:: Anft M, Wiemers L, Rosiewicz KS, et al. Effect of immunoadsorption on clinical presentation and immune alterations in COVID-19-induced and/or aggravated ME/CFS. Molecular Therapy. 2025;33(6):2886–2899. DOI:: 10.1016/j.ymthe.2025.01.007 PMID:: 39797400 Published:: 2025 Institution:: Marien Hospital Herne / Ruhr-University Bochum (independent of Charit'e Berlin) Study Design:: Observational study; n=12 post-COVID patients with ME/CFS symptoms and elevated autonomic nervous system receptor autoantibodies Key Findings:: Autoantibodies nearly eliminated after IA. Pro-inflammatory cytokines reduced (IL-4, IL-2, IL-1\(\beta\), TNF, IL-17A) and soluble spike protein decreased. At 30 days: improved neuropsychological function and modest but statistically significant improvement in hand grip strength. However, self-reported ME/CFS symptom questionnaire scores were not significantly improved. Autoantibody and cytokine levels rebounded within one month. Relevance:: Independent replication of IA immunological effects from a different German institution, providing external validation of the Charit'e immunological findings. The discordance between objective immune/grip-strength improvements and subjective symptom questionnaires is important: it suggests either (a) the symptom questionnaires are insensitive at n=12, (b) autoantibody rebound within a month prevents sustained improvement, or (c) ME/CFS symptoms are not primarily autoantibody-driven. Certainty:: Low-Medium (n=12 only; observational; no sham control; symptom scores non-significant; rebound within 30 days limits clinical conclusions. Immunological findings: Medium strength).
Full Citation:: EXTINCT Trial. NCT05954325. Extracorporal Apheresis Hannover Medical School Study in Post COVID-19 Patients. ClinicalTrials.gov. ClinicalTrials:: NCT05954325 Institution:: Hannover Medical School, Hanover, Germany Study Design:: Double-blind, randomized, sham-controlled RCT; n=63; 5 IA sessions within 14 days; start date 2023-08-15; completed (verified September 2025) Primary Endpoint:: Chalder Fatigue Scale at 12 weeks Key Findings:: Trial registration only — results not yet published at time of writing (April 2026). The trial is completed and results are awaited. Relevance:: Second sham-controlled RCT of immunoadsorption in ME/CFS/post-COVID. Independent of Charit'e Berlin (Hannover Medical School). Larger than any single Charit'e cohort. Double-blind sham-controlled design allows definitive assessment of placebo effect of invasive apheresis procedures. Results will be pivotal for the field. Certainty:: Trial design: High quality. Efficacy certainty: Pending publication.
Full Citation:: IMPACT Trial. NCT07529197. Observational Study on Immunoadsorption (IA) in Patients With Autoantibody-Positive Post-Infectious ME/CFS. ClinicalTrials.gov. ClinicalTrials:: NCT07529197 Institution:: Charit'e – Universit"atsmedizin Berlin, Germany Study Design:: Non-interventional prospective observational cohort; n=50 estimated; 5 outpatient IA sessions on days 1, 2, 4, 6, 8; start date 2026-03-11; recruiting Primary Endpoint:: SF-36 Physical Function at 8 weeks Secondary Endpoints:: Memory B-cell changes, autoantibody reduction, Chalder Fatigue Scale, COMPASS-31 autonomic score, handgrip strength, work ability Key Findings:: Trial registration only — ongoing as of April 2026. Relevance:: Novel focus on memory B-cell dynamics distinguishes IMPACT from prior IA studies. If IA produces durable responses in some patients, memory B-cell depletion/reprogramming is a plausible mechanism; if responses are short-lived (as in Anft 2025), memory B-cells may be the missing link. Outpatient design is also notable: previous studies required hospitalization, limiting access. IMPACT will test whether outpatient IA achieves comparable effects. Certainty:: Trial registration only — no efficacy data.
Full Citation:: Loebel M, Grabowski P, Heidecke H, et al. Antibodies to beta adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome. Brain Behav Immun. 2016;52:32–39. DOI:: 10.1016/j.bbi.2015.09.013 PMID:: 26399744 Published:: February 2016 Study Design:: Case-control study with autoantibody profiling Key Findings:: Original landmark study identifying elevated autoantibodies against \(\beta\)-adrenergic receptors (\(\beta\) 1, \(\beta\) 2) and muscarinic acetylcholine receptors (M3, M4) in ME/CFS patients. Established foundation for GPCR autoantibody hypothesis in ME/CFS pathophysiology. Relevance:: First systematic documentation of GPCR autoantibodies in ME/CFS. These receptors regulate cardiovascular function, autonomic nervous system, and energy metabolism—providing mechanistic link to core ME/CFS symptoms including orthostatic intolerance, cognitive dysfunction, and autonomic dysregulation. Certainty:: High (published in Brain Behav Immun, replicated in multiple subsequent studies including Sotzny 2021 and Bynke 2020).
Full Citation:: Freitag H, Szklarski M, Lorenz S, Sotzny F, et al. Autoantibodies to Vasoregulative G-Protein-Coupled Receptors Correlate with Symptom Severity, Autonomic Dysfunction and Disability in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. J Clin Med. 2021;10(16):3675. DOI:: 10.3390/jcm10163675 PMID:: 34441971 Published:: August 2021 Study Design:: Cross-sectional correlation study Key Findings:: Demonstrated dose-response relationship between GPCR autoantibody levels and symptom severity, autonomic dysfunction severity, and disability scores. Autoantibodies against \(\beta\) 2-adrenergic, M3, and M4 receptors showed strongest correlations. Relevance:: Critical evidence that autoantibodies are not merely present but functionally relevant—their levels predict clinical severity. Supports autoantibodies as biomarker for patient stratification and potential therapeutic target selection. Certainty:: High (symptom correlation strengthens causal inference, published in peer-reviewed journal, consistent with mechanistic studies).
Full Citation:: Bynke A, Julin P, Gottfries CG, Heidecke H, Scheibenbogen C, Bergquist J. Autoantibodies to beta-adrenergic and muscarinic cholinergic receptors in Myalgic Encephalomyelitis (ME) patients—A validation study in plasma and cerebrospinal fluid from two Swedish cohorts. Brain Behav Immun Health. 2020;7:100107. DOI:: 10.1016/j.bbih.2020.100107 Published:: August 2020 Study Design:: Validation study in independent Swedish cohorts with CSF analysis Key Findings:: Validated Loebel 2016 findings in two independent Swedish ME/CFS cohorts. Importantly, detected GPCR autoantibodies in cerebrospinal fluid in addition to plasma, demonstrating central nervous system exposure to autoantibodies. Relevance:: Independent international validation strengthens evidence for GPCR autoantibodies in ME/CFS. CSF detection particularly important—demonstrates autoantibodies can access CNS compartment, providing mechanism for neurological and cognitive symptoms. Certainty:: High (independent replication in separate geographic population, CSF analysis adds mechanistic insight).
Full Citation:: Hohberger B, et al. Case Report: Neutralization of Autoantibodies Targeting G-Protein-Coupled Receptors Improves Capillary Impairment and Fatigue Symptoms After COVID-19 Infection. Front Med. 2021;8:754667. DOI:: 10.3389/fmed.2021.754667 PMID:: 34869451 Published:: November 2021 Study Design:: Case report with BC007 aptamer treatment Key Findings:: BC007 DNA aptamer neutralized GPCR autoantibodies in Long COVID patient, resulting in improved capillary blood flow (documented by nailfold capillaroscopy) and reduced fatigue symptoms. Provided proof-of-concept for targeted autoantibody neutralization. Relevance:: First demonstration that neutralizing GPCR autoantibodies improves objective vascular parameters and symptoms. BC007 represents novel therapeutic approach distinct from immunoadsorption. Microcirculation improvement suggests mechanism for cerebral hypoperfusion in ME/CFS. Certainty:: Medium (single case report limits generalizability; objective capillary measurements strengthen evidence; awaits controlled trials).
Full Citation:: Hackel A, Sotzny F, Mennenga E, et al. Autoantibody-Driven Monocyte Dysfunction in Post-COVID Syndrome with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. medRxiv [Preprint]. 2025. DOI:: 10.1101/2025.01.09.25320264 Published:: January 2025 Study Design:: In vitro mechanistic study with patient-derived autoantibodies Key Findings:: GPCR autoantibodies from post-COVID ME/CFS patients reprogram monocyte function, altering cytokine secretion and inflammatory responses. Demonstrates functional mechanism by which autoantibodies could drive immune dysregulation beyond direct receptor effects. Relevance:: Extends GPCR autoantibody hypothesis beyond autonomic/vascular effects to include immune cell reprogramming. Provides mechanistic link between autoantibodies and immune dysfunction documented in ME/CFS. Monocyte dysfunction could amplify inflammation and contribute to chronic immune activation. Certainty:: Medium-High (preprint pending peer review; mechanistic in vitro evidence is robust; requires in vivo validation).
Full Citation:: Azcue N, Prada A, Del Pino R, et al. Involvement of autoantibodies against G protein-coupled receptors in post-COVID condition and Chronic Fatigue Syndrome. Scientific Reports. 2026;16:in press. (Azcue et al. 2026) DOI:: 10.1038/s41598-026-49131-9 Published:: 2026 Study Design:: Case-control study (n=59 ME/CFS, n=96 PCC, n=36 HCs) Key Findings:: Beta2-adrenergic AAb titers significantly higher in ME/CFS vs PCC and HCs (F₂,₁₈₆=3.15, p=0.046). Beta2 AAb correlated with sympathovagal imbalance (r=0.45, p=0.001). M1, M3, M4 AAbs positively correlated with verbal/working memory. Distinct PCC vs ME/CFS antibody profiles suggest trigger-specific immunological trajectories. Conclusion:: Confirms GPCR autoantibody involvement in ME/CFS and PCC with strongest autonomic-autoantibody correlation to date. Limitations:: Moderate sample size; CellTrend ELISA specificity concerns (Germain 2025 null, Vernino 2022 POTS null); single study. ME/CFS Relevance:: Provides strongest quantitative link between beta2-adrenergic AAbs and sympathovagal imbalance in ME/CFS. Certainty Assessment::
- *Quality:*: Medium (Scientific Reports, cross-sectional)
- *Sample:*: n=191
- *Replication:*: Single study; partially converges with earlier GPCR literature but uses different assays
- *Score:*: 0.55Full Citation:: Germain A, Jaycox JR, Emig CJ, Ring AM, Hanson MR. An In-Depth Exploration of the Autoantibody Immune Profile in ME/CFS Using Novel Antigen Profiling Techniques. International Journal of Molecular Sciences. 2025;26(6):2799. (Germain et al. 2025) DOI:: 10.3390/ijms26062799 Published:: 2025 Study Design:: Case-control study with REAP and Luminex platforms Key Findings:: Used REAP (1,284 antigens) and Luminex (including GPCRs) in well-characterised ME/CFS cohort. No significant autoantibody differences found between ME/CFS and controls on either platform. Contradicts earlier CellTrend ELISA-based studies (Wirth 2021, Azcue 2026). Important methodological contribution: demonstrates that autoantibody findings are platform-dependent. Conclusion:: Largest and most rigorous autoantibody screen in ME/CFS to date; null finding constrains the GPCR autoantibody hypothesis. Limitations:: Single cohort; REAP may miss conformational epitopes; sample size limited for subgroup analysis. ME/CFS Relevance:: Critical counterweight to GPCR autoantibody literature. Suggests CellTrend ELISA findings may reflect platform-specific artifacts or conformational epitopes not captured by REAP. Certainty Assessment::
- *Quality:*: High (novel antigen profiling, well-characterised cohort)
- *Sample:*: Moderate
- *Replication:*: Single study
- *Score:*: 0.65Full Citation:: Wallukat G, Homuth V, Fischer T, et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. Journal of Clinical Investigation. 1999;103(7):945-952. (Wallukat et al. 2021b) DOI:: 10.1172/JCI4106 Published:: 1999 Study Design:: Case-control study with functional bioassay Key Findings:: First demonstration that GPCR autoantibodies can be functionally active (agonistic) and directly pathogenic. Established methodological paradigm for functional autoantibody testing. Conclusion:: Landmark study establishing functional GPCR autoantibody paradigm. ME/CFS Relevance:: Provides methodological framework for determining whether ME/CFS GPCR AAbs are functionally active or merely bystander antibodies. Certainty Assessment::
- *Quality:*: High (JCI, landmark)
- *Sample:*: Moderate
- *Replication:*: Extensively replicated
- *Score:*: 0.85Full Citation:: Sotzny F, Filgueiras IS, Kedor C, et al. Dysregulated autoantibodies targeting vaso- and immunoregulatory receptors in Post-COVID Syndrome correlate with symptom severity. Frontiers in Immunology. 2022;13:949259. (Sotzny et al. 2022) DOI:: 10.3389/fimmu.2022.949259 Published:: 2022 Study Design:: Case-control study with GPCR ELISA panels Key Findings:: Dysregulated autoantibodies targeting vaso- and immunoregulatory receptors in post-COVID syndrome. Correlation with symptom severity confirmed. Extended GPCR autoantibody findings from ME/CFS to post-COVID population. Conclusion:: Replicates GPCR autoantibody findings in post-COVID population. ME/CFS Relevance:: Supports shared autoantibody mechanism across post-infectious syndromes. Certainty Assessment::
- *Quality:*: Medium
- *Sample:*: Moderate
- *Replication:*: Consistent with Wirth 2021
- *Score:*: 0.60Full Citation:: Blaes F, Schmitz K, Tschernatsch M, et al. Autoimmunity against the beta2-adrenergic receptor and muscarinic-2 receptor in complex regional pain syndrome. PAIN. 2011;152(12):2690–2700. (Blaes, Wallukat, et al. 2011) DOI:: 10.1016/j.pain.2011.06.012 Published:: 2011 Study Design:: Case-control study with functional cardiomyocyte bioassay Key Findings:: Identified functional autoantibodies against beta2-AR and M2-mAChR in CRPS patients using validated cardiomyocyte bioassay. Autoantibodies showed receptor-activating (agonistic-like) properties. First demonstration that GPCR autoantibodies can produce autonomic dysfunction in humans. Conclusion:: Existence proof that GPCR AAbs cause autonomic dysfunction. ME/CFS Relevance:: Demonstrates that GPCR AAbs can be causally linked to autonomic symptoms. However, CRPS AAbs show agonistic activity while ME/CFS AAbs (CellTrend ELISA) have undetermined functional status — parallel is suggestive but not direct evidence. Certainty Assessment::
- *Quality:*: High (functional bioassay, PAIN journal)
- *Sample:*: n=20 CRPS
- *Replication:*: Replicated by subsequent studies
- *Score:*: 0.65Full Citation:: Scheibenbogen C, Loebel M, Freitag H, et al. Immunoadsorption to remove beta2-adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME. PLoS ONE. 2018;13(5):e0193672. (Scheibenbogen et al. 2018) DOI:: 10.1371/journal.pone.0193672 Published:: 2018 Study Design:: Open-label pilot study (n=10) Key Findings:: Removing beta2-AR autoantibodies via immunoadsorption improved fatigue and functional capacity. Autoantibody levels correlated with symptom severity. First proof-of-concept for autoantibody-targeted therapy in ME/CFS. Conclusion:: Established feasibility of autoantibody-targeted therapy. Limitations:: Open-label, no sham, n=10. ME/CFS Relevance:: Launched entire immunoadsorption research program. All subsequent IA studies build on this pilot. Certainty Assessment::
- *Quality:*: Low-Medium (pilot, open-label)
- *Sample:*: n=10
- *Replication:*: Extended by Stein 2023, 2025
- *Score:*: 0.40Full Citation:: Hohberger B, Góschel LP, Schober M, et al. Case Report: Neutralization of Autoantibodies Targeting G-Protein-Coupled Receptors Improves Capillary Impairment and Fatigue Symptoms After COVID-19 Infection. Frontiers in Medicine. 2021;8:754667. (Hohberger et al. 2021) DOI:: 10.3389/fmed.2021.754667 Published:: November 2021 Study Design:: Case report with BC007 aptamer treatment Key Findings:: BC007 DNA aptamer neutralized GPCR autoantibodies in a Long COVID patient, improving capillary flow (nailfold capillaroscopy) and reducing fatigue. First demonstration of targeted pharmacological autoantibody neutralization. Conclusion:: Proof-of-concept for aptamer-based autoantibody neutralization. Limitations:: Single case report; no control. ME/CFS Relevance:: If GPCR AAbs are pathogenic in ME/CFS, BC007 or similar aptamers could provide targeted therapy distinct from immunoadsorption. Microcirculation improvement suggests mechanism for cerebral hypoperfusion. Certainty Assessment::
- *Quality:*: Low (case report)
- *Sample:*: n=1
- *Replication:*: Single case
- *Score:*: 0.35Full Citation:: Gunning WT, Kvale H, Kramer PM, Karabin BL, Grubb BP. Postural Orthostatic Tachycardia Syndrome Is Associated With Elevated G-Protein Coupled Receptor Autoantibodies. Journal of the American Heart Association. 2019;8(18):e013602. (Gunning et al. 2019) DOI:: 10.1161/JAHA.119.013602 Published:: 2019 Study Design:: Case-control study with CellTrend ELISA Sample Size:: n=55 POTS patients, n=63 healthy controls Key Findings:: 89% of POTS patients had elevated autoantibodies to ≥1 GPCR (α1, β1, β2, M2, M4). Highest prevalence for α1-AR (65%) and β2-AR (60%). First comprehensive GPCR autoantibody profiling in POTS. Conclusion:: GPCR autoantibodies are highly prevalent in POTS and correlate with symptom severity. ME/CFS Relevance:: Establishes the CellTrend ELISA platform used in subsequent ME/CFS studies. Same antibody targets found in ME/CFS (Loebel 2016, Bynke 2020) and Long COVID (Wallukat 2021). Certainty Assessment::
- *Quality:*: High (JAHA, controlled)
- *Sample:*: Moderate (n=118)
- *Replication:*: Replicated (Lund, Charité)
- *Score:*: 0.65Full Citation:: Fedorowski A, Li H, Yu X, et al. Antiadrenergic autoimmunity in postural orthostatic tachycardia syndrome. Europace. 2017;19(7):1211–1219. (Fedorowski et al. 2017) DOI:: 10.1093/europace/euw154 Published:: 2017 Study Design:: Case-control with functional cell-based bioassay (CHO cells) Sample Size:: n=17 POTS patients, n=12 healthy controls Key Findings:: POTS patient IgG activated α1-AR in CHO cell bioassay (increased Ca2+ flux). β1/β2-AR autoantibodies also detected. 8/17 POTS patients showed positive functional response. First functional demonstration. Conclusion:: POTS autoantibodies are functionally active, not merely binding. ME/CFS Relevance:: Establishes Koch-like criterion for autoantibody pathogenicity. Same functional bioassay could test ME/CFS IgG. Certainty Assessment::
- *Quality:*: High (Europace, functional bioassay)
- *Sample:*: Small (n=17)
- *Replication:*: Replicated (Kharraziha 2020)
- *Score:*: 0.70Full Citation:: Wallukat G, Hohberger B, Wenzel K, et al. Functional autoantibodies against G-protein-coupled receptors in patients with persistent Long-COVID-19 symptoms. Journal of Translational Autoimmunity. 2021;4:100100. (Wallukat et al. 2021a) DOI:: 10.1016/j.jtauto.2021.100100 Published:: 2021 Study Design:: Case-control with functional cardiomyocyte bioassay Sample Size:: n=50 Long COVID patients, n=30 healthy controls Key Findings:: Long COVID patients had functionally active β2-AR autoantibodies that increased cardiomyocyte beating rate — effect blocked by β2-AR antagonist. Autoantibody activity correlated with symptom severity. Conclusion:: GPCR autoantibodies in Long COVID are functionally active. ME/CFS Relevance:: Demonstrates functionally active GPCR autoantibodies in a post-infectious syndrome overlapping with ME/CFS. Certainty Assessment::
- *Quality:*: Medium-High (functional bioassay)
- *Sample:*: Moderate
- *Replication:*: Consistent with POTS and ME/CFS literature
- *Score:*: 0.70Full Citation:: Li J, Zhang Q, Weng T, et al. Autoimmune basis for postural tachycardia syndrome. Journal of the American Heart Association. 2014;3(1):e000755. (Li et al. 2014) DOI:: 10.1161/JAHA.113.000755 Published:: 2014 Study Design:: Case-control with multiple autoimmune assays Key Findings:: POTS patients had elevated autoimmune markers including anti-Na+/K+-ATPase and GPCR autoantibodies. First study from the Oklahoma group. Conclusion:: Autoimmune mechanisms contribute to POTS pathogenesis. ME/CFS Relevance:: Foundation study for autoimmune POTS paradigm later extended to ME/CFS. Certainty Assessment::
- *Quality:*: Medium-High (JAHA)
- *Sample:*: Moderate
- *Replication:*: Extended (Li 2019 rabbit, Fedorowski 2017)
- *Score:*: 0.65Full Citation:: Li J, Zhang Q, Weng T, et al. Adrenergic autoantibody-induced postural tachycardia syndrome in rabbits. Journal of the American Heart Association. 2019;8(24):e013640. (Li et al. 2019) DOI:: 10.1161/JAHA.119.013640 Published:: 2019 Study Design:: Passive transfer animal model Key Findings:: Rabbit passive transfer of POTS patient IgG induced tachycardia, abnormal HR response to orthostasis. Purified adrenergic autoantibodies recapitulated the phenotype. First causal animal model. Conclusion:: Adrenergic autoantibodies are causal in POTS. ME/CFS Relevance:: Satisfies Koch-like criterion for autoantibody pathogenicity. Provides experimental template for ME/CFS IgG passive transfer. Certainty Assessment::
- *Quality:*: High (JAHA, functional animal model)
- *Sample:*: Small
- *Replication:*: Consistent with Fedorowski 2017
- *Score:*: 0.55Full Citation:: Kharraziha I, Li H, Ulander M, Cujic D, Fedorowski A. Serum activity of G protein-coupled receptor autoantibodies and severity of orthostatic symptoms in postural orthostatic tachycardia syndrome. Scientific Reports. 2020;10:7220. (Kharraziha et al. 2020) DOI:: 10.1038/s41598-020-64197-5 Published:: 2020 Study Design:: Cross-sectional with functional bioassay Sample Size:: n=50 POTS (Lund cohort extension) Key Findings:: GPCR autoantibody functional activity correlated with orthostatic symptom severity. Different profiles (α1, β2, M2) associated with different symptom patterns. Conclusion:: Dose-response relationship between autoantibody activity and severity. ME/CFS Relevance:: Supports causality via dose-response criterion. Methodology applicable to ME/CFS. Certainty Assessment::
- *Quality:*: Medium-High (Sci Rep, functional assay)
- *Sample:*: Moderate (n=50)
- *Replication:*: Extends Fedorowski 2017
- *Score:*: 0.60Full Citation:: Sunami Y, Wirth K, Schimrosczyk K, et al. Association of autoantibodies against G protein-coupled receptors with gastrointestinal symptoms in myalgic encephalomyelitis/chronic fatigue syndrome. Journal of Translational Medicine. 2024;22:518. (Sunami et al. 2024) DOI:: 10.1186/s12967-024-05297-4 Published:: 2024 Study Design:: Cross-sectional with CellTrend ELISA Key Findings:: M3 muscarinic autoantibodies significantly associated with GI dysmotility in ME/CFS. GI severity correlated with M3 titer. Conclusion:: M3 autoantibodies link GPCR autoimmunity to GI symptoms in ME/CFS. Certainty Assessment::
- *Quality:*: Medium (J Transl Med)
- *Sample:*: Moderate
- *Score:*: 0.65Full Citation:: Shin YW, Kim J, Kim HJ, et al. Human Leukocyte Antigen-Associated Postural Orthostatic Tachycardia Syndrome: Evidence for Autoimmune Pathogenesis. Scientific Reports. 2019;9:15013. (Shin et al. 2019) DOI:: 10.1038/s41598-019-51438-9 Published:: 2019 Study Design:: Case-control HLA association study Sample Size:: n=93 Korean POTS, n=196 controls Key Findings:: HLA-DRB115:01 and DQB106:02 associated with POTS (OR > 2.5). First autoimmune genetic predisposition evidence. Conclusion:: POTS has HLA-associated autoimmune genetic predisposition. ME/CFS Relevance:: Same alleles untested in ME/CFS. If present, would provide direct genetic evidence for shared autoimmune mechanisms. Certainty Assessment::
- *Quality:*: Medium-High (Sci Rep, controlled)
- *Sample:*: Moderate (Korean cohort)
- *Replication:*: Not yet replicated
- *Score:*: 0.65Full Citation:: El-Rhermoul ZZ, Fedorowski A, Li H, et al. Autoimmunity in long COVID and POTS. Autonomic Neuroscience: Basic and Clinical. 2023;249:103120. (El-Rhermoul et al. 2023) DOI:: 10.1016/j.autneu.2023.103120 Published:: 2023 Study Design:: Narrative review Key Findings:: Synthesizes autoimmune mechanisms in Long COVID and POTS: GPCR autoantibodies, ganglionic AChR, elevated autoimmune comorbidity, immunomodulatory treatment responses. Conclusion:: Autoimmunity is central to both Long COVID and POTS. ME/CFS Relevance:: Provides framework for shared autoimmune mechanisms across post-infectious syndromes. Certainty Assessment::
- *Quality:*: Medium (narrative review)
- *Score:*: 0.60Full Citation:: Blitshteyn S. Autoimmune markers and autoimmune disorders in patients with postural tachycardia syndrome (POTS). Autonomic Neuroscience: Basic and Clinical. 2015;195:51–54. (Blitshteyn 2015) DOI:: 10.1016/j.autneu.2015.07.004 Published:: 2015 Study Design:: Retrospective chart review Sample Size:: n=100 POTS patients Key Findings:: 37% ANA+. Elevated autoimmune comorbidity: Hashimoto (22%), SLE (5%), Sjögren’s (3%). First systematic documentation. Conclusion:: POTS associated with elevated autoimmune markers and comorbidity. ME/CFS Relevance:: Sjögren’s finding directly supports the M3 autoantibody bridge hypothesis. Certainty Assessment::
- *Quality:*: Medium (retrospective, single-center)
- *Sample:*: n=100
- *Replication:*: Replicated
- *Score:*: 0.65Full Citation:: Ruzieh M, Batizy LH, Dasa O, Oostra C, Grubb BP. The role of autoantibodies in the syndromes of orthostatic intolerance: a systematic review. Scandinavian Cardiovascular Journal. 2017;51(5):243–249. (Ruzieh et al. 2017) DOI:: 10.1080/14017431.2017.1356468 Published:: 2017 Study Design:: Systematic review Key Findings:: GPCR autoantibodies consistently found across orthostatic intolerance syndromes. Ganglionic AChR antibodies in a subset. Conclusion:: Autoantibodies are consistently associated with orthostatic intolerance. ME/CFS Relevance:: Contextualizes GPCR antibodies within broader orthostatic intolerance literature. Certainty Assessment::
- *Quality:*: Medium (systematic review)
- *Score:*: 0.55Full Citation:: Blitshteyn S, Doherty TA, Steinman L. POTS, ME/CFS, and Long COVID: a convergent neuroimmune framework. Annals of Clinical and Translational Neurology. 2026. (Blitshteyn, Doherty, and Steinman 2026) DOI:: 10.1002/acn3.70001 Published:: 2026 Study Design:: Narrative synthesis / perspective Key Findings:: Synthesizes evidence across POTS, ME/CFS, Long COVID into convergent neuroimmune framework: GPCR autoantibodies, brainstem neuroinflammation, cholinergic anti-inflammatory pathway dysfunction, shared immunomodulatory treatment patterns. Proposes spectrum model. Conclusion:: Unified neuroimmune framework for POTS, ME/CFS, and Long COVID. Limitations:: Narrative synthesis; variable evidence quality across pillars; single-proponent perspective. ME/CFS Relevance:: Primary framework paper for the neuroimmune hypothesis. Provides foundation for the Blitshteyn 2026 integration in this volume. Certainty Assessment::
- *Quality:*: Medium-High (synthesis, leading authors)
- *Score:*: 0.852 Tatai2026 — Tissue-Specific Autoantibodies in Long COVID
Full Citation:: Tatai O, Nagy S, Nguyen THT, et al. Tissue-specific autoantibody signatures reveal immune alterations undetected by routine serology in long COVID. GeroScience. 2026. DOI:: https://doi.org/10.1007/s11357-026-02286-9 Key Findings::
- Tissue-specific autoantibodies: cardiac 54%, vascular 34%, pulmonary 34% in long COVID patients (n=114 long COVID, n=36 controls)
- IgM-dominated (60 pct vs 36 pct in controls, p $\leq 0.05$)
- NOT detected by routine ANA HEp-2 testing (83% seropositive on Western blot vs.\ no discriminatory value on ANA)
- Associated with neurovascular manifestations: hypertension, headache, anosmia, ageusia
- CRP only marginally elevated in seropositive individuals
- Polyreactive pattern (up to 8 distinct bands per patient)
- Follow-up (n=30, 141 days): persistent IgM and emergence of new autoantibodiesConclusion:: IgM-dominant tissue-specific autoantibodies are prevalent in long COVID, invisible to standard ANA screening, and associated with neurovascular symptoms. Suggests ongoing immune dysregulation with failed/atypical class switching. Limitations:: Single study, moderate sample size, not yet independently replicated. Western blot uses denatured antigens (may detect linear epitopes not relevant in vivo). Control group small (n=36).
3 TRPM3 Ion Channel Dysfunction
Full Citation:: Sasso E, Smith P, Marshall-Gradisnik S, et al. Multi-site validation of TRPM3 ion channel dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Frontiers in Medicine. 2026. DOI:: 10.3389/fmed.2025.1703924 Published:: January 13, 2026 Institution:: Griffith University, National Centre for Neuroimmunology and Emerging Diseases (NCNED) Study Design:: Multi-site validation study using gold-standard techniques Key Findings::
- TRPM3 ion channel (a calcium-permeable channel in immune cells) functions abnormally in ME/CFS patients compared to healthy controls
- Defect reproducibly observed across independent laboratories over 4,000 km apart (Gold Coast and Perth, Australia)
- Faulty ion channels act like “stuck doors,” preventing cells from receiving calcium needed for immune functionSignificance:: Provides robust, multi-site validated evidence of measurable cellular abnormalities in ME/CFS. Supports development of diagnostic tests and identifies potential therapeutic targets. Offers greater recognition of ME/CFS as a legitimate medical condition with objective biological markers. Lead Researchers:: Professor Sonya Marshall-Gradisnik (Director), Dr. Etianne Sasso (Lead Author), Dr. Peter Smith
4 Immune Exhaustion and Chronic Activation
Full Citation:: Immune exhaustion in ME/CFS and long COVID. JCI Insight. 2024;9(19):e183810. DOI:: 10.1172/jci.insight.183810
5 Cytokine Biomarkers and Immune Signatures
Hornig et al. 2015 — Duration-Dependent Cytokine Signatures
Key Findings: This landmark study in Science Advances identified distinct immune signatures in ME/CFS that vary by disease duration. Among 298 ME/CFS patients and 348 controls, early-stage patients (<3 years) showed prominent activation of both pro- and anti-inflammatory cytokines, including elevated IL-1\(\alpha\), IL-8, IL-10, IL-12p40, IL-17F, IFN-\(\gamma\), CXCL1, CXCL9, and IL-5. In stark contrast, patients with longer disease duration (>3 years) had normalized cytokine levels. A 17-cytokine panel distinguished early ME/CFS from controls with high accuracy.
Relevance: Provides the strongest evidence to date that ME/CFS immunopathology evolves over time, potentially from initial immune activation to exhaustion or adaptation. This duration-dependent pattern explains heterogeneity in previous cytokine studies that failed to stratify by illness duration and suggests therapeutic windows where early intervention may be more effective.
Certainty Assessment:
- Quality: High (published in Science Advances, large sample size, rigorous methodology)
- Sample: n=646 total (298 ME/CFS, 348 controls)
- Replication: Partially replicated in Montoya 2017 and Che 2025
- Limitations: Cross-sectional design cannot track individual progression; mechanism of cytokine normalization unclear
Montoya et al. 2017 — Cytokine-Severity Correlation
Key Findings: This PNAS study demonstrated dose-response relationships between cytokines and symptom severity. Although only two cytokines differed overall between patients and controls (TGF-\(\beta\) higher, resistin lower), 17 cytokines showed significant upward linear trends correlating with disease severity. Thirteen of these 17 are proinflammatory: CCL11, CXCL1, CXCL10, IFN-\(\gamma\), IL-4, IL-5, IL-7, IL-12p70, IL-13, IL-17F, G-CSF, GM-CSF, and TGF-\(\alpha\). CXCL9 inversely correlated with fatigue duration, consistent with Hornig 2015’s duration-dependent findings.
Relevance: Provides evidence that immune activation tracks with symptom burden. The dose-response relationship (rather than binary patient-control comparison) suggests cytokine profiling could stratify patients for clinical trials and identify those likely to benefit from immunomodulatory therapies. Complements Hornig 2015 by focusing on severity rather than duration.
Certainty Assessment:
- Quality: High (published in PNAS, large sample, Stanford affiliation)
- Sample: n=584 (192 ME/CFS, 392 controls)
- Replication: Partially replicated in Che 2025
- Limitations: Cross-sectional; cannot determine causality; severity assessment subjective
Che et al. 2025 — Sex-Specific Immune Dysregulation
Key Findings: Multi-omics study from the Walitt/Lipkin group demonstrated exaggerated innate immune responses to microbial stimulation in ME/CFS, with IL-6 and other proinflammatory cytokines elevated before and markedly increased after exercise. Critically, hyperinflammatory responses were amplified in women over 45 years with diminished estradiol levels, suggesting sex hormone-immune interactions. The study also identified impaired energy production (TCA cycle dysfunction, fatty acid oxidation defects) that worsened post-exercise.
Relevance: Extends previous cytokine findings to reveal sex- and age-specific patterns. The estradiol-cytokine relationship provides mechanistic insight into female predominance of ME/CFS and suggests potential therapeutic interventions (estrogen supplementation for older women). Integrates immune and metabolic dysfunction, supporting multi-system pathophysiology model.
Certainty Assessment:
- Quality: High (Nature portfolio journal, rigorous multi-omics approach)
- Sample: Specific n not provided in abstract
- Replication: Confirms and extends Hornig/Montoya cytokine findings
- Limitations: Sex-hormone mechanism needs further validation
Giloteaux et al. 2023 — IL-2 in Extracellular Vesicles
Key Findings: Novel study examining cytokine content in extracellular vesicles (EVs) rather than free plasma. IL-2 was significantly elevated in ME/CFS patient EVs. Proinflammatory cytokines CSF2 and TNF\(\alpha\) correlated with physical and fatigue symptom severity. EVs represent cell-to-cell signaling mechanism and may better reflect active immune communication.
Relevance: Identifies IL-2 as potentially important cytokine in ME/CFS pathophysiology. Notably, Hunter 2025 independently identified IL-2 pathway using epigenetic methods, providing convergent evidence from different methodologies. EV-based analysis may reveal immune signals missed by conventional plasma assays.
Certainty Assessment:
- Quality: Medium-High (novel methodology, peer-reviewed)
- Sample: n=98 (49 ME/CFS, 49 controls)
- Replication: IL-2 finding supported by Hunter 2025; EV method needs replication
- Limitations: Single study with novel methodology; EV assays less standardized than plasma
Hunter et al. 2025 — Epigenetic Biomarkers and IL-2 Pathway
Key Findings: Developed blood-based diagnostic test using EpiSwitch technology identifying 200 chromosome conformation markers that distinguish ME/CFS from controls with 92% sensitivity and 98% specificity. Pathway analysis revealed involvement of IL-2, TNF\(\alpha\), toll-like receptor signaling, and JAK/STAT mechanisms. IL-2 identified as shared pathway with existing therapies (Rituximab, glatiramer acetate).
Relevance: Provides epigenetic validation of immune pathways identified by cytokine studies. High diagnostic specificity (98%) suggests potential clinical utility. IL-2 pathway finding converges with Giloteaux 2023, supporting IL-2 as therapeutic target. Study focused on severely affected patients.
Certainty Assessment:
- Quality: Medium-High (peer-reviewed, high diagnostic accuracy)
- Sample: n=108 (47 ME/CFS, 61 controls)
- Replication: Single study; proprietary technology limits independent validation
- Limitations: Severe patients only; EpiSwitch technology not commercially available for clinical ordering — this is a research-stage proprietary platform, not a test clinicians can currently request; needs independent cohort validation
6 Natural Killer Cell Dysfunction
Eaton-Fitch et al. 2019 — Systematic Review of NK Cell Function
Key Findings: This systematic review examined 17 observational case-control studies published between 1994–2018. Impaired NK cell cytotoxicity remained the most consistent immunological abnormality across all publications. Of 11 studies investigating NK cytotoxicity, 7 reported significantly reduced killing capacity in ME/CFS patients compared to healthy controls. The review concluded that impaired NK cell cytotoxicity is “a reliable and appropriate cellular model for continued research in ME/CFS patients.”
Relevance: Provides high-quality systematic evidence that NK cell dysfunction is one of the most replicated findings in ME/CFS research, spanning over two decades of independent studies. Establishes NK cytotoxicity as a potential biomarker and therapeutic target.
Certainty Assessment:
- Quality: High (systematic review published in Systematic Reviews journal)
- Sample: 17 independent case-control studies reviewed
- Replication: Highly replicated (7 of 11 studies confirmed reduced NK cytotoxicity)
- Limitations: Heterogeneity in measurement methods across studies; mechanisms remain unclear
Maher et al. 2005 — Perforin Deficiency in CFS NK Cells
(Maher, Klimas, and Fletcher 2005)
Key Findings: This mechanistic study demonstrated that CFS patients have 45% reduction in NK cell perforin content (3,320 vs 6,051 rMol/cell, \(p = 0.01\)) compared to healthy controls. Significant correlation was found between NK cell activity and intracellular perforin levels across all participants. Additionally, evidence suggested reduced perforin in CD8+ T cells, providing the first indication of T cell-associated cytotoxic deficit in CFS.
Relevance: Provides a molecular mechanism explaining why NK cells in CFS have impaired cytotoxicity: insufficient perforin prevents effective target cell killing even when NK cells successfully recognize their targets. Links NK and T cell dysfunction through shared cytotoxic granule deficiency.
Certainty Assessment:
- Quality: High (published in Clinical and Experimental Immunology, direct molecular measurement)
- Sample: Not specified in abstract
- Replication: Single study; findings consistent with broader NK dysfunction literature
- Limitations: Mechanism of perforin deficiency unclear; needs replication in larger cohorts
Brenu et al. 2011 — Comprehensive Immune Profiling (n=95)
Key Findings: Large comprehensive study (n=95 CFS/ME patients, n=50 controls) examining multiple immune parameters. Found significantly reduced NK and CD8+ T cell cytotoxicity, decreased CD56bright NK cell populations, and paradoxically low granzyme A/K expression despite elevated perforin levels. Cytokine analysis revealed elevated IL-10 (anti-inflammatory), IFN-\(\gamma\), and TNF-\(\alpha\) (pro-inflammatory), suggesting simultaneous activation and suppression. Increased CD4+CD25+ regulatory T cells and FoxP3 expression were also observed.
Relevance: One of the largest comprehensive immune profiling studies in ME/CFS. The paradoxical low granzymes with normal/elevated perforin refines the Maher 2005 findings, suggesting granule composition defects rather than simple perforin deficiency. Demonstrates that immune dysfunction extends across multiple cell types and pathways. Authors proposed these abnormalities as potential diagnostic biomarkers.
Certainty Assessment:
- Quality: High (large sample, published in Journal of Translational Medicine, comprehensive methodology)
- Sample: n=145 total (95 CFS/ME, 50 controls)
- Replication: Confirms NK/T cell dysfunction from other studies; granzyme findings novel
- Limitations: Cross-sectional; cannot determine causality; heterogeneous patient population
7 T Cell Metabolic Dysfunction
Mandarano et al. 2020 — T Cell Bioenergetic Deficits
Key Findings: First comprehensive metabolic analysis of T cells in ME/CFS (n=53 patients, n=45 controls). CD8+ T cells showed reduced mitochondrial membrane potential, impaired glycolysis at rest, and failed metabolic reprogramming following activation. Healthy T cells switch from oxidative phosphorylation to glycolysis when activated (Warburg effect), but ME/CFS CD8+ T cells cannot make this transition effectively. CD4+ T cells also demonstrated reduced baseline glycolysis. ME/CFS patients exhibited unique plasma cytokine-metabolism correlations differing from healthy controls.
Relevance: Bridges immune dysfunction and bioenergetic impairment chapters, demonstrating that metabolic deficits extend to immune cells. Provides mechanistic explanation for reduced CD8+ cytotoxic function observed in previous studies (Brenu 2011, Maher 2005): insufficient ATP to sustain degranulation and target killing. Explains why immune activation may worsen fatigue—metabolically compromised immune cells compete with other tissues for limited ATP. Published in top-tier Journal of Clinical Investigation.
Certainty Assessment:
- Quality: Very High (JCI publication, large sample, direct metabolic measurements)
- Sample: n=98 total (53 ME/CFS, 45 controls)
- Replication: Single study; novel methodology
- Limitations: Cross-sectional; mechanism linking mitochondrial dysfunction to immune dysfunction unclear
8 Neutrophil Dysfunction
Kennedy et al. 2004 — Increased Neutrophil Apoptosis
Key Findings: CFS patients (n=47) demonstrated increased neutrophil apoptosis compared to controls (n=34): 37.4% vs 22.8% annexin V binding (\(p = 0.001\)), elevated TNFRI death receptor expression (\(p = 0.004\)), and raised active TGF-\(\beta\) 1 concentrations (\(p < 0.005\)). Higher apoptosis resulted in lower numbers of viable neutrophils. Authors concluded this represents “an underlying, detectable abnormality in the behavior of their immune cells, consistent with an activated inflammatory process.”
Relevance: Demonstrates that immune dysfunction in CFS extends beyond lymphocytes to innate immune cells (neutrophils). Increased apoptosis suggests accelerated neutrophil turnover and may impair antimicrobial defense. Links neutrophil dysfunction to elevated TNF-\(\alpha\) found in cytokine studies, providing mechanistic connection. Supports concept of “activated but exhausted” immune phenotype.
Certainty Assessment:
- Quality: Moderate-High (published in Journal of Clinical Pathology, clear statistical significance)
- Sample: n=81 total (47 CFS, 34 controls)
- Replication: Single study; needs independent replication
- Limitations: Functional consequences of increased apoptosis not directly measured; mechanism unclear
9 Autoantibodies: Historical Context
Nishikai 2007 — ANA Prevalence and 68/48 kDa Autoantibodies
Key Findings: Review of Nishikai’s research program on autoantibodies in CFS. Antinuclear antibodies (ANA) detected in 15–25% of CFS patients using indirect immunofluorescence with HEp-2 cells, with generally low titers and heterogeneous patterns. Specific autoantibodies to 68/48 kDa protein found in 13.2% of CFS patients and 15.6% of fibromyalgia patients, compared to 0% of healthy controls (\(p < 0.05\)). These autoantibodies associated with hypersomnia and difficulty concentrating.
Relevance: Represents pioneering early work (1990s–2000s) establishing that a subset of CFS patients have autoimmune markers, though the majority (75–85%) are ANA-negative. Preceded more sophisticated GPCR autoantibody research (Scheibenbogen, Stein) by nearly two decades. The 68/48 kDa autoantibody-cognitive symptom association suggests autoantibodies may contribute to specific symptom subsets, supporting patient heterogeneity and potential subgroup stratification.
Certainty Assessment:
- Quality: Moderate (multiple studies by same group, peer-reviewed)
- Sample: Various studies; 2001 study had n=114 CFS patients
- Replication: Limited independent replication; findings preceded modern GPCR autoantibody era
- Limitations: Less specific autoantibody assays than current methods; functional significance of ANA unclear; 68/48 kDa target not fully characterized
10 Comprehensive Immune Reviews
Full Citation:: Komaroff AL, Lipkin WI. ME/CFS and Long COVID share similar symptoms and biological abnormalities: road map to the literature. Frontiers in Medicine. 2023;10:1187163. DOI:: 10.3389/fmed.2023.1187163 PMCID:: PMC10278546 Significance:: Comprehensive comparison of ME/CFS and Long COVID biological abnormalities.
Full Citation:: Komaroff AL, Lipkin WI. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: the biology of a neglected disease. Frontiers in Immunology. 2024;15:1386607. DOI:: 10.3389/fimmu.2024.1386607 PMCID:: PMC11180809